Bloodstream infections (BSIs) due to vancomycin-resistant Enterococcus faecium (VREfae) remain a therapeutic challenge. This study aimed to evaluate mortality from BSIs due to VREfae in Central Taiwan.
Introduction
The management of bloodstream infections (BSIs) due to Enterococcus faecium, particularly those due to vancomycinresistant enterococci (VRE), has become a therapeutic challenge. BSIs due to vancomycin-resistant E faecium (VREfae) were first reported in 1988, and a short time later, they were reported in the USA and European countries. [1] The first VRE BSI in Taiwan was reported in 1996. [2] In the USA, VRE has become an important nosocomial pathogen, and their ratio among all nosocomial pathogens has increased from 0.3% in 1989 to nearly 30% in 2003 according to data from the National Nosocomial Infections Surveillance System. [3] In addition, VRE accounts for 14% of the enterococcal isolates among patients in intensive care units (ICUs). [3] Although VRE represented <2% of the enterococci identified in an antimicrobial resistance surveillance program in Taiwan in 2000, [4] a rapid increase in vancomycin resistance from 12.4% in 2007 to 42.0% in 2016 among nosocomial enterococcal isolates in ICU was reported by the Taiwan Nosocomial Infection Surveillance System. [5] The persistence of E faecium is a cause for concern because the treatment options and infection control measures are limited, and there is a low clinical awareness. Therefore, BSIs due to VREfae are an important clinical issue.
Most studies on BSI due to enterococcal infections focus on the general infection, geography of the infection, and vancomycin resistance. [6, 7] In addition, the majority of studies published to date have been conducted in the USA, where the epidemiological conditions differ from those occurring in Asia. [8] The risk factors associated with in-hospital mortality from BSIs due to E faecium have been reported, [9] but most of these factors are indicators in basic medical sciences, and the molecular biomarkers are not useful to physicians. Furthermore, information regarding BSIs due to VREfae in Central Taiwan is particularly scarce. [9] [10] [11] An increasing resistance rate to vancomycin among enterococcal isolates has been documented globally. [12] The clonal spread of certain epidemic VREfae strains belonging to clonal complex 17 (CC17) contributed to this increase. [13] Therefore, the aim of the present study was to analyze the clinical features and microbiological characteristics of BSIs due to VREfae in Central Taiwan.
Materials and methods

Clinical setting and study population
The population living in the rural areas of Central Taiwan is mostly served by the Changhua Christian Hospital System (CCHS), which consists of 4000 beds. The Changhua Christian Hospital (CCH) is the largest hospital among 9 branch hospitals in the CCHS and is an 1800-bed tertiary referral medical center situated in Central Taiwan. This study was conducted in the CCHS and was approved by the institutional review board of CCH. Cases of BSIs due to VREfae were analyzed by reviewing the medical records, and a cross-sectional retrospective study was conducted between January 1, 2010 and December 31, 2014 in the CCHS.
Patient identification, patient analysis, and definition
The occurrence of symptomatic enterococcal BSI was defined as >2 blood cultures positive for Enterococcus sp. or a single blood culture positive for Enterococcus sp. combined with a significant source of infection. Patients with BSI due to VREfae were identified from the microbiological databases and medical records according to the ninth edition of the International Classification of Diseases, with some clinical modifications (ICD-9-CM) in the CCHS in Central Taiwan. We used computerized indices to identify cases with the following ICD-9-CM codes: V09.8, 041.04, 790.7, 038, and 038.9. All the patients documented with BSI due to VREfae were enrolled during the study period. The exclusion criteria included age <18 years, inadequate clinical data, inconsistency between the data from the ICD-9 code and the microbiological dataset, and misinterpretation of the microbiological examinations. A standardized case report form was used to collect the data contained in the medical records regarding the medical diagnoses, medical treatment, and other key information. The medical records of all cases involving BSI due to VREfae were manually reviewed by the primary investigator (CCH) to confirm the diagnosis (using CCHS resources). Clinically equivocal cases were discussed and decisions were made by the primary and the secondary investigator (CCY). Only the first episode of BSI due to VREfae in each patient during the study period was included in the statistical analysis.
The date of the onset of BSI was defined as the date on which the culture from the first blood sample was positive. The case group was defined as BSIs due to vancomycin-resistant E faecium (VREfae), and the control group was defined as enterococcal BSIs other than VREfae. Polymicrobial bacteremia was defined as the presence of >1 microorganism from the same blood culture specimen. The underlying severity was classified according to the McCabe and Jackson criteria. [14] During the initial 24 hours from the onset of BSI due to VREfae, the systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock were defined as previously described. [15] The source of infection was defined as the site of infection where it was microbiologically and clinically documented. [15] The outcome was evaluated 30 days after the onset of BSI due to VREfae in the CCHS. Death was considered associated with BSI when the patient died <2 weeks after the onset of BSI, and no other cause of death was identified. The all-cause 30-day mortality group was defined as patients with BSI due to VREfae who died within 30 days of diagnosis. BSI due to VREfae was classified as healthcare-onset or communityacquired according to a modified version of Horan's description. [16] An appropriate antimicrobial therapy was defined as patients who received effective antibiotics as evaluated by susceptibility tests during the period of effective empirical therapy.
Microbiological identification, susceptibility test, and molecular analysis
Between January 1, 2010 and December 31, 2014, all VREfae isolates cultured from blood samples were considered significant findings, and 36 clinical isolates were identified as VRE in the CCHS in Central Taiwan. Only the initial isolate from each patient was analyzed. The laboratory identification of Enterococcus spp. was performed using the 6.5% NaCl/bile-esculin agar test and confirmed with the Vitek-2 gram-positive identification system (bioMérieux, Marcy l'Etoile, France) at CCHS. Then, those isolates were sent to a reference laboratory (Research Laboratory, Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital) for reconfirmation. The susceptibility to various antimicrobial agents by determination of MICs was performed with the Vitek-2 system (bioMérieux, Marcy l'Etoile, France). [17] The following drugs were tested: ampicillin, ciprofloxacin, erythromycin, linezolid, minocycline, penicillin, rifampin, teicoplanin, tigecycline, and vancomycin. The interpretive criteria of the Clinical and Laboratory Standards Institute (CLSI) were used to determine the isolate susceptibility. [17] Vancomycin resistance was defined as an minimum inhibitory concentration (MIC) ≥32 mg/mL.
The genotypes of VREfae were determined using polymerase chain reaction (PCR)-based methods as described previously. [18] Multilocus sequence typing (MLST) for VREfae was also performed as previously reported. [19] 
Statistical analysis
Continuous variables were expressed as the mean ± standard deviation or the median and range if the distribution was not normal and were compared using Student's t-test or MannWhitney U test. Continuous data were expressed as the mean ± standard deviation or as the median and range. Univariate and multivariate analyses were performed to determine the independent risk factors for the all-cause 30-day mortality using logistic regression models. A P-value <.05 was considered statistically significant. All tests were performed using SPSS V.17.0 for Windows (SPSS Inc, Chicago, IL).
Results
Study population
Two hundred seventy-nine patients at CCHS were found to have a positive blood culture for enterococci. Among them, 177 patients were at CCH, and the other 102 patients were at other branches of CCHS. Symptomatic BSI was identified in 194
Chen et al. 96: 49 Medicine patients after excluding duplicates from 21 patients. Thirty-eight patients were excluded because 30 patients had incomplete data, and 8 patients were clinically determined to be without significant evidence of an infection; therefore, 152 patients were analyzed ( Fig. 1 ).
Clinical features of the case group (BSI due to VREfae) and control group (BSI other than VREfae)
The epidemiological characteristics and underlying conditions of the 152 patients are shown in VREfae, and none received oral vancomycin. The 30-day mortality rate was 13.2% (20 of 152 patients). There were significant statistical differences between VREfae BSI and enterococcal BSI other than VREfae BSI upon admission at the medical ICU in terms of the onset of BSI (P = .035) and the appropriate antimicrobial therapy (P = .025). The multivariate logistic regression analysis, including a univariate analysis of variables with P <.05, showed that the onset of VREfae BSI in ICUs (odds ratio [OR] = 4.2, 95% confidence interval [CI] = 1.7-10, P = .002) was the only significant risk factor for 30-day mortality. An appropriate antimicrobial therapy was a protective factor for 30-day mortality (OR = 0.33, 95% CI = 0.14-0.79, P = .013).
Microbiological characteristics of 36 VREfae
The antibiotic susceptibility of the 36 VREfae isolates is shown in (Fig. 2) . Chen et al. Table 1 Clinical features of patients in the case group (VREfae BSI) and control group (enterococcal BSI other than VREfae).
Characteristic Control, n = 116 (%) Case, n = 36 (%) All, n = 152 (%) P Data is reported in number (%) of patients, unless otherwise indicated. BSI = bloodstream infections, SIRS = systemic inflammatory response syndrome, VREfae = vancomycin-resistant Enterococcus faecium. * Some patients had >1 underlying disease (or risk factors). † Leukocyte count <4000 mm. ‡ Within the past month. x Receipt of steroid therapy for >10 days or use of other immunosuppressant (tacrolimus, mycophenolate mofetil, azathioprine, cyclosporine A, or anti-CD3 monoclonal antibody) for 11 weeks within the previous 1 month. jj The analysis of hospital-acquired cases only included those acquired at Changhua Christian Hospital System. ¶ Death from all causes within 30 days.
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Discussion
This is the first study to describe the clinical features of BSI due to VREfae and identify the microbiological characteristics of VREfae in Central Taiwan. After comparing our results with those of other recent studies on BSI due to Enterococcus sp., we noted that the proportion (7.6%) of enterococcal BSI was similar to that of the total BSI episodes (5.0%-7.1%). [20, 21] The proportion (23.7%) of VREfae BSI was in good agreement with previous results. [9, 22, 23] VREfae infections in food-producing animals derived from broiler production have also been reported. [24] We observed that the 30-day mortality rate (20/152, 13.2%) from VREfae BSI among our patients was lower than that observed in previous studies. [20, 25] The lower mortality rate observed may be due to multiple factors, including patient populations, variations in the portal of entry, serious underlying conditions, and lack of lethal clonal spread. However, further experiments are needed to elucidate these factors. The emergence of antimicrobial-resistant bacteria, including VREfae, poses a difficult task for physicians who have limited therapeutic options. Critically ill patients admitted to ICUs are at a major risk of being infected with resistant bacteria that will have an adverse impact on mortality. [26] Jung's study showed that VREfae colonization was associated with increased mortality, [27] and the results of our study showed that the onset of VREfae BSI in the ICU was another significant risk factor for 30-day mortality (OR = 4.2, 95% CI = 1.7-10.0, P = .002). The length of ICU stay, which may reflect the severity of BSI, was also strongly associated with the odds of death from BSI due to VREfae. [27] Certainly, critically ill patients admitted to the ICUs are at a major risk of mortality, and VREfae can play an important role as the causative agent. In addition, an appropriate antimicrobial therapy for VREfae BSI was a protective factor for 30-day mortality (OR = 0.33, 95% CI = 0.14-0.79, P = .013). The results of our study were similar to the results of other studies. [27] Importantly, the results of the present study suggest that an appropriate antimicrobial therapy results in lower odds of all-cause 30-day mortality. The international guidelines for the management of severe sepsis and septic shock recommend the administration of broadspectrum antimicrobials within 1 hour of the diagnosis of septic shock (1B) and severe sepsis without septic shock (1C) as the goal of therapy. [28] Therefore, we highlight the need to address the patients admitted to the ICU with VREfae BSI and use Chen et al. (Fig. 2 ).
An increasing resistance rate to vancomycin among enterococcal isolates has been documented globally. [12] The clonal spread of certain epidemic VREfae strains belonging to CC17 contributed to this increase. [13] The 2 major STs among the VREfae isolates tested in our study, ST-17 and ST-78, all belong to CC17, which might explain the same increasing trend of vancomycin resistance in Taiwan. A previous study demonstrated that ST-78 was the epidemic strain causing VRE infections in Taiwan in 2007. [29, 30] Our study showed that the VREfae isolates of ST-18 and ST-414 were first noted before 2010. However, in 2010 and 2014, ST-17 and ST-78 became the predominant STs, which temporally correlated with the rapid increase in VREfae. Because of the small sample size of individual STs in this study, an accurate correlation between STs and mortality rate cannot be calculated. Among the blood enterococcal isolates, 23.7% (36/ 152) were VREfae, and all 36 VREfae remained highly susceptible to linezolid and tigecycline. ST-17 and ST-78 were the 2 predominant STs during the study period. The pathogenicity and virulence of predominant VREfae STs warrants further study. We assumed that no predominant clonal spread occurred in the study year due to the absence of outbreaks.
The present study has several strengths. Most importantly, we accumulated a complete longitudinal dataset over 4 years. We had access to excellent data to evaluate the demographic features of VREfae BSI. In addition, the present findings provide invaluable epidemiological information about BSI due to VREfae in Central Taiwan.
Our study has several limitations. The first limitation was that our facility was unable to perform the molecular typing of the isolates; therefore, the clonality and genotypes of the isolates could not be evaluated. Second, we could described the correlation between ICU stay and VREfae BSI for all-cause 30-day mortality, but the causality analysis between ICU stay and VREfae BSI could not be clearly established due to retrospective analysis. We suggested each episode of BSI at ICU should serve patient aggressively and carefully. Third, our microbiological laboratory did not evaluate the microbial susceptibility to daptomycin. We assessed the adequacy of the antibiotic therapy using the in vitro breakpoint method reported by CLSI. [17] Vancomycin therapy for strains with MIC 32 mg/ mL was regarded as adequate. Lastly, some data suggest that resistance may be inducible in some strains. [29] Therefore, vancomycin therapy against infection due to vanC-VRE has been regarded as inadequate. Furthermore, vanC genotype was not included in this study, but we can assume that a similar phenomenon has occurred in our institute, as previously reported. [23] In conclusion, our results suggest that onset of VREfae BSI at ICU was the only significant risk factors for all-cause 30-day mortality. An appropriate antimicrobial therapy was a protective factor for 30-day mortality. Therefore, we highlight the need to use appropriate antimicrobial therapy in patients admitted to the ICUs with VREfae BSIs with the aim to treat more patients with these infections.
